The Indiana homecare enteral feeding formula market size was valued at USD 70.8 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.6% from 2021 to 2028. The demand for enteral feed formulations, such as the growing geriatric population and the rising prevalence of chronic disorders, including diabetes, neurological disorders, cardiovascular diseases, hypertension, and stroke, are some of the key factors anticipated to boost market growth. Rapid globalization coupled with the pursual of unhealthy lifestyles is leading to an increasing prevalence of malnourishment. The rising demand for preterm and neonatal clinical nutrition is driving the market for homecare enteral feeding formula. Moreover, the unmet demand for disease-specific formulations to manage specific or rare diseases is boosting the active market players to constantly focus on their product innovation and development.
The surge in the prevalence of chronic conditions with the rapid growth in the geriatric population is the key impact-rendering driver for the market over the forecast period. There has been a constant increase in the prevalence of chronic diseases, such as Alzheimer's disease, Attention Deficit Hyperactivity Disorder (ADHD), osteoporosis, osteoarthritis, central nervous system disorders, and other diseases, which require clinical dietary management. As per the American Cancer Society’s Cancer Statistics Center, Indiana is expected to have 39,010 new cases in 2021 and 13,460 cancer-related deaths in 2021. As per American Diabetes Association, in 2018, Indiana accounted for approximately 695,832 cases of diabetes and 35.6% of the population was pre-diabetic with high blood glucose levels. In Indiana, every year there are an estimated 33,000 people diagnosed with diabetes. As per the U.S. CDC, many of these conditions are preventable through simple lifestyle changes, such as cessation of smoking, physical activity, and a healthy diet. An increase in the number of people suffering from chronic conditions is one of the key factors anticipated to boost the market for homecare enteral feeding formula over the forecast period.
The increasing incidence of targeted diseases is boosting market players to innovate disease-specific formulas for clinical nutrition management. These specific formulations are widely used in the treatment of cancer and cystic fibrosis. For instance, Nestle specializes in personalized clinical nutritional formulations such as Deplin for depression and Metanx for diabetes. These factors drive demand for clinical nutrition in homecare settings by helping enhance the effectiveness of treatment and improving the overall quality of medical treatment. The high prevalence of preterm births and the rising need for pediatric nutrition are expected to boost the market for homecare enteral feeding formula. In addition, as per statistics quoted by WHO, in 2018, the number of preterm births in the country was 517,400. Also, in the state of Indiana, in 2018, one in every ten infants were pre-term births. Therefore, the high incidence of preterm births in the Indiana state, coupled with improving healthcare infrastructure and growing healthcare expenditure and patient awareness, is expected to be a high impact rendering driver for the market during the forecast period.
Post COVID Outlook
The Indiana homecare enteral feeding formula market increased by 8.5% from 2019 to 2020
The market is estimated to witness a y-o-y growth of approximately 7% to 8% in the next five years.
Covid-19 positive patients are diagnosed with impaired immunity, weakened digestion, and disruption of respiratory and other systems. These patients require clinical nutrition support, and thus an increase in the adoption of enteral tube feeding has been witnessed.
As the Journal of the Academy of Nutrition and Dietetics states, most of the Covid-19 positive patients admitted to the ICU suffer from acute malnourishment. The long-lasting impact of the Covid-19 infection boosts the demand for clinical nutritional support. In turn, it will contribute to the growth of the enteral feeding formula market in Indiana.
The deficiency of micronutrients and vitamins in Covid-19 positive patients contributes to the growing demand for enteral feed formulations.
An increase in hospitalization for Covid-19 patients has boosted the demand for enteral feeding formulations to meet the nutrition requirements of the patients. Market players are devising strategies to overcome manufacturing and supply chain disruptions caused due to the Covid-19 restrictions. In addition, to the efforts undertaken by private players, U.S. government authorities introduced a Value-based Insurance Design (V-BID) model by CMS to provide favorable reimbursement scenarios.
Advancements in enteral feeding formulations for disease-specific, neonatal care, and rare disease management are expected to boost the market for homecare enteral feeding formula. For instance, in August 2020, Kate Farms launched two new organic plant-based products-Kate Farms Pediatric Peptide 1.0 formula and Kate Farms Standard 1.4 formula. The new offerings joined the company’s robust portfolio to support patients with chronic diseases who are experiencing intolerance owing to subpar ingredients that are found in legacy brands. In October 2018, Hormel Foods added products to its Vital Cuisine range for providing nutrition to cancer patients. It will help in expanding the company’s product portfolio about cancer nutrition. The growing clinical nutrition market is receiving recognition in the form of investments from private equity firms and venture capitalists to promote product development.
For instance, in November 2020, Kate Farms closed USD 51 million funding in Series B funding round. This investment was led by Goldman Sachs and Kaiser Permanente Ventures and existing individual investors. With aid of this round of funding, Kate Farms will be able to grow its plant-based liquid nutrition formulations, drive overall innovation, and further expand its business. Key players are focusing on their mergers and acquisition strategies to expand their business footprint. For instance, in October 2020, Real Food Blends was acquired by Danone’s Nutricia. Post this acquisition, Real Food Blends product offerings will be able to reach more markets and cater to a larger consumer base. Nutricia’s longstanding experience in children and adult specialized nutrition will expedite product growth. Through this acquisition, Nutricia will gain access to financial and operational resources.
The ongoing Covid-19 pandemic has positively impacted the market for homecare enteral feeding formula in Indiana. As per studies, Covid-19 positive patients have experience weakened immunity and disrupted respiratory and other systems. Most Covid-19 patients develop gastrointestinal disorders or face other abdominal problems. According to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffer from acute malnourishment. Hence, the usage of enteral feeding formulas is expected to increase in both homecare settings and hospital settings.
In 2020, the standard formula segment dominated the market for homecare enteral feeding formula and accounted for the largest revenue share of 62.3%. This is attributable to the high usage of enteral feed for basic clinical nutrition supplementation, easy commercial availability, and growing investment by major market players. These standard nutrition formulas are used to fulfill macro and micronutrient requirements in patients. These ready-to-use formulas are available in powdered form or may require reconstitution with milk or water. Moreover, increasing demand for low-cost nutrient formulations is one of the crucial factors anticipated to drive the market for homecare enteral feeding formula in the coming years.
However, the disease-specific formulas segment is expected to witness the fastest growth in the market for homecare enteral feeding formula over the forecast period. These formulations deliver nutritional support to patients suffering from specific diseases associated with organ dysfunctions. For instance, Glucerna by Abbott and Boost Glucose Control by Nestlé are examples of specialized formulas for patients suffering from diabetes. However, specialized products may contain common food allergens, such as soy, milk, wheat, and corn, owing to the high caloric density of these products with low water content. The patients are required to increase their water intake.
In 2020, the intermittent feeding flow segment dominated the market for homecare enteral feeding formula and accounted for the largest revenue share of 94.0%. This is attributable to the growing need of administering nutritional formulas at certain intervals using a large feeding syringe and a feeding pump or gravity drip bag. The benefits associated with intermittent feeding flow formulations are increased patient mobility and physiological efficiency concerning gut homeostasis and digestion. It is anticipated to record the fastest growth for the forecast period owing to the growing geriatric population, rising prevalence of chronic diseases, increasing demand for disease-specific formulas, and growing demand for clinical nutritional formulations in preterm and neonatal care.
Pediatric patients with a dysfunctional gastrointestinal tract are unable to ingest nutrients orally and hence administered enteral feeding. Tube feeding is also provided to pediatric patients suffering from gastrointestinal disorders such as various allergies, severe gastroesophageal reflux, food refusal behavior, and metabolic disorders that may be congenital, anatomical, or both.
In 2020, the adults' segment dominated the market for homecare enteral feeding formula and accounted for the largest revenue share of 91.0%. This segment is anticipated to witness the fastest growth for the forecast period. This growth is attributable to the growing economic burden associated with malnutrition of approximately USD 42 billion. Malnourished or undernourished patients suffer from impaired immunity and poor muscle strength. Lack of consistent access to food has been termed as “food insecurity” by USDA. For instance, according to “Feeding Indiana's Hungry”, 15 percent of the population accounting for 1,009,710 individuals and 335,410 children in Indiana are food insecure. The growing demand for such nutrition formulations in the adult population is one of the crucial factors anticipated to boost the market for homecare enteral feeding formula in the coming few years.
In 2020, the others segment dominated the Indiana homecare enteral feeding formula market and accounted for the largest revenue share of 49.9%. This is attributable to the growing burden of chronic diseases in the population. Clinical nutrition is required in critically ill patients suffering from ailments such as cystic fibrosis, chronic obstructive pulmonary disease, postoperative stress disorders, and severe burns. In malnourished critically ill patients with the impaired immune system, the need for clinical nutrition is high. For instance, Pulmocare, an Abbott product, is used as an enteral feed for the treatment of these conditions. Conditions, such as inflammation, postoperative stress, and infections, can also be treated with the help of enteral feed. For instance, Danone provides Nutrition Protein Plus and Nutrition Protein Plus Fibre, which are useful in treating infections, postoperative stress disorders, and severe burns. On the other hand, orphan diseases are expected to record the fastest growth rate over the forecast period.
According to an article published by the Genetic and Rare Diseases Information Center (GARD), around 25 million to 30 million people in the U.S. were living with some form of a rare disease in 2017. Furthermore, patients suffering from rare diseases associated with genetic syndromes, such as Costello syndrome and Russell-Silver syndrome, are likely to use tube feeding as an option to gain nutrition. Due to an increase in awareness about enteral nutrition options and a rise in the detection and diagnosis of orphan diseases, the market is estimated to grow steadily in the coming years.
Some of the key market players are continuously investing in the discovery and development of innovative enteral feeding formulations to serve growing clinical nutrition needs and gain a competitive edge over others in the market, which is expected to drive market growth. For instance, in December 2020, Abbott expanded its Pedialyte product portfolio with four new formulations to support the immune system: Pedialyte with immune support, Pedialyte Sport, Pedialyte Organic, and Pedialyte Electrolyte Water with zero sugar. In addition, they are also adopting various strategies such as mergers and acquisitions and expanding their manufacturing facilities to strengthen their business and expand the product offerings. Some of the prominent players in the Indiana homecare enteral feeding formula market include:
Mead Johnson & Company, LLC
Byram Healthcare Centers, Inc.
Real Food Blends
Shield Healthcare, Inc.
Nutritional Medicinals LLC
Market size value in 2021
USD 76.4 million
Revenue forecast in 2028
USD 127.9 million
CAGR of 7.6% from 2021 to 2028
Base year for estimation
2016 - 2019
2021 - 2028
Revenue in USD million and CAGR from 2021 to 2028
Revenue, company ranking, competitive landscape, growth factors, and trends
Product, flow type, stage, and indication
Key companies profiled
Mead Johnson & Company, LLC; Byram Healthcare Centers, Inc; Real Food Blends; Shield Healthcare, Inc; Nutritional Medicinals LLC; Kate Farms
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research, Inc. has segmented the Indiana homecare enteral feeding formula market report on the basis of product, flow type, stage, and indication:
Product Outlook (Revenue, USD Million, 2016 - 2028)
Flow Type Outlook (Revenue, USD Million, 2016 - 2028)
Intermittent Feeding Flow
Continuous Feeding Flow
Stage Outlook (Revenue, USD Million, 2016 - 2028)
Indication Outlook (Revenue, USD Million, 2016 - 2028)
Chronic Kidney Disease
Malabsorption/ GI Disorder/ Diarrhea
b. The Indiana homecare enteral feeding formulas market size was estimated at USD 70.8 million in 2020 and is expected to reach USD 76.4 million in 2021.
b. The Indiana homecare enteral feeding formula market is expected to grow at a compound annual growth rate of 7.6% from 2021 to 2028 to reach USD 127.9 million by 2028.
b. Standard formulas product segment dominated the Indiana homecare enteral feeding formula market owing to the availability of a wide variety of standard formulas along with increasing demand for low-cost nutrient formulations.
b. Some key players operating in the Indiana homecare enteral feeding formula market include Mead Johnson & Company; Shield Healthcare; Kate Farms; Byram Healthcare Centers; Real Food Blends; and Nutritional Medicinals.
b. The growing prevalence of chronic diseases, such as cancer, stroke, dementia, Chronic Obstructive Pulmonary Disease (COPD), chronic liver disease, multiple sclerosis, and diabetes, is projected to drive the demand for enteral feeding formulations that support patients with oral intake issues.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."